The company will spotlight the breast cancer risk stratification software Volpara Risk Pathways and a new mammography training collaboration with Mammography Educators.
Recognizing the shift from age-based breast cancer screening to screening programs that are more focused on risk stratification, Volpara will be spotlighting its Volpara Risk Pathways™ software at the annual Society of Breast Imaging (SBI)/American College of Radiology (ACR) conference in Savannah, Ga. this week.
Drawing upon patient data from mammography reporting systems or electronic health records, Volpara Risk Pathways reportedly facilitates the identification and management of patients who are at high risk for breast cancer, according to Volpara. The company said the software’s assessment of an individual’s risk for breast cancer enables enhanced triage decisions for supplemental imaging and/or genetic testing.
Volpara will also spotlight the Analytics in Action program, which offers on-site training from Mammography Educators.
“The Analytics in Action program is designed to help deliver high-quality, personalized breast cancer screening by improving image quality, reducing errors, and increasing proficiency and efficiency. We are excited for our partnership with Volpara to deliver hands-on, personalized training sessions designed not only to help address common positioning performance issues but also to create a culture of quality and continuous improvement that ultimately will result in better screening and better patient care,” noted Louise Miller, R.T. (R)(M)(ARRT), CRT, FSBI, FNCBC, the director of education and co-founder of Mammography Educators.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.